IQVIA Holdings, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Michael Ryskin from Bank of America Securities reiterated a Buy rating on the stock and has a $215.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Michael Ryskin’s rating is based on IQVIA Holdings’ strong second-quarter performance and positive business-to-business metrics, which exceeded expectations and drove a significant increase in stock value. The company’s R&D Solutions segment demonstrated robust net business-to-business growth, and the overall results alleviated concerns about potential cyclical or structural challenges in the contract research organization sector.
Despite some margin compression due to increased services and pricing pressures, IQVIA’s aggressive market approach and higher request-for-proposal volumes with enterprise business partners indicate a strong competitive position. Ryskin remains confident in IQVIA’s long-term EBITDA margin expansion and has updated the price objective to $215, reflecting a positive outlook on the company’s future performance and market positioning.
In another report released yesterday, Evercore ISI also maintained a Buy rating on the stock with a $220.00 price target.
IQV’s price has also changed slightly for the past six months – from $205.420 to $187.380, which is a -8.78% drop .